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Obstructive sleep apnea is recognized as having high prevalence and causing remarkable cardiovascular risk. Coronary artery
disease has been associated with obstructive sleep apnea in many reports. The pathophysiology of coronary artery disease in
obstructive sleep apnea patients probably includes the activation of multiple mechanisms, as the sympathetic activity, endothelial
dysfunction, atherosclerosis, and systemic hypertension. Moreover, chronic intermittent hypoxia and oxidative stress have an
important role in the pathogenesis of coronary disease and are also fundamental to the development of atherosclerosis and other
comorbidities present in coronary artery diseases such as lipid metabolic disorders. Interestingly, the prognosis of patients with
coronary artery disease has been associated with obstructive sleep apnea and the severity of sleep disordered breathing may have
a direct relationship with the morbidity and mortality of patients with coronary diseases. Nevertheless, treatment with CPAP may
have important effects, and recent reports have described the benefits of obstructive sleep apnea treatment on the recurrence of
acute heart ischaemic events in patients with coronary artery disease.
1. Introduction
Obstructive sleep apnea (OSA) is a common medical con-
dition characterized by abnormal collapse of the pharyngeal
airway during sleep, causing repetitive arousals, and drops in
the oxygen saturation. It is highly prevalent in the general
population [1] and it acts as an independent risk factor for
hypertension (HT) [2, 3]. In addition, several studies have
suggested that OSA is associated with other cardiovascular
diseases such as heart failure [4], arrhythmias [5], pulmonary
hypertension [6], and coronary artery disease (CAD).
Although mortality from CAD has fallen since 1975, it is
still a major cause of death and disability in developed coun-
tries. The high prevalence of cardiovascular risk factors in
the general population (diabetes mellitus, cigarette smoking,
obesity, hypertension, and lack of regular physical activity)
facilitates the development of atherosclerosis in coronary
arteries and, subsequently, the presence of CAD. Although
clinical guidelines for the management of CAD still do not
consider OSA as a specific risk factor, results from the Sleep
Heart Health Study have shown that OSA may increase
the risk of CAD inmiddle-agedmenwith an apnea-hypopnea
index (AHI) ≥ 30 h−1 [7].
2. Association between Obstructive Sleep
Apnea and Coronary Artery Disease
Several cross-sectional and epidemiological studies have
evaluated the association between OSA and CAD. In a case-
control study, Mooe et al. [8] selected 102 women with CAD
and 50 age-matched controls and reported that CAD patients
had a higher prevalence of sleep breathing disorders than
the control group (AHI ≥ 5 h−1: 54% versus 20%, 𝑃 <
0.0001; AHI ≥ 10 h−1: 31% versus 18%, 𝑃 < 0.05, resp.).
These findings were also described in men, where authors
observed that 37% of patients with CAD had an AHI ≥
10 h−1 [9]. Despite their interesting findings, these studies had
several limitations. For instance, important cardiovascular
risk factors, such as cholesterol levels, were not included in
the analysis. Also, in the manual score of the sleep study,
authors did not discriminate between central and obstructive
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apneas. And finally, a questionnaire was only used about
coronary symptoms to exclude CAD in the control subjects.
A similar association had been found in a population cross-
sectional study. Shahar et al. [10], analyzed the association
between OSA and self-reported cardiovascular disease in
6.424 individuals who underwent overnight polysomnog-
raphy from the Sleep Heart Health Study. They showed
that subjects with the highest quartile of AHI (AHI > 11
events h−1) had an adjusted ratio of 1.27 for self-reported
CAD. Recently, Gottlieb et al. [7] have found a significant
association between severe OSA and coronary heart disease
in middle-aged men from the Sleep Heart Health Study, and
they reported a significant association between severe OSA
and coronary heart disease in middle-aged men.
There is some evidence suggesting that the prevalence and
the severity of OSA are modified along the CAD evolution.
Moruzzi et al. [11] performed overnight polysomnographic
studies in three groups of CAD patients: immediately after
an acute myocardial infarction (AMI) (group 1), after clinical
stabilization of unstable angina (group 2), and with stable
angina (group 3). They observed a significantly higher AHI
in groups 1 and 2 compared with group 3 (11.1 ± 19.4 h−1,
14.7 ± 5.20 h−1, and 2.8 ± 6.4 h−1, resp.; 𝑃 < 0.01). However,
studies from Mooe et al. [8] and Moruzzi et al. [11] did
not adjust properly for confounding factors. So Peker et al.
[12] performed a case-control study adjusted for several
cardiovascular risk factors that included hypertension, hyper-
cholesterolemia, diabetes, and smoking, and compared the
results of sleep recording studies of 62 patients admitted
in the coronary care unit due to acute CAD and 62-age-,
sex-, and BMI-matched control subjects without history or
signs of heart disease. OSA (AHI ≥ 10 h−1) was present in
19 CAD patients but only in 8 control subjects (𝑃 = 0.017).
In the multiple logistic regression analysis, current smoking
(odds ratio [OR] 9.8, 95% CI 2.6–36.5), diabetes (OR 4.2,
95% CI 1.1–17.1), and OSA (OR 3.1, 95% CI 1.2–8.3) were
independently associated with coronary disease. However,
this study also had several limitations as the high prevalence
of hypercholesterolemia in both groups (>80% of patients),
the sleep diagnostic procedure used, and the substantial
delay between the cardiac event and the sleep study (4–
21 months). Supporting the relationship between OSA and
CAD, Lee et al. [13] and Nakashima et al. [14] have also found
similar results and they have observed a moderate-severe
OSAS (AHI≥ 15 h−1) in 43% and 65.7% of subjects with CAD,
respectively. Despite the high prevalence of OSA reported
in patients with CAD, it is frequently underdiagnosed. One
study demonstrated that OSA was initially suspected in
only 12% of patients admitted with myocardial infarction
(MI) whereas, after an overnight polysomnography, 70% of
patients presented an AHI ≥ 5 h−1 and 41% an AHI ≥ 15 h−1
[15].
There are several explanations for the difference in the
OSA prevalence among the aforementioned studies. The
definition of the ideal timing forOSA screening after an acute
cardiovascular event remains unresolved. Skinner et al. [16]
performed two overnight sleep studies in patients with CAD
(MI, unstable angina or congestive heart failure): at the time
of acute presentation in the Coronary Care Unit and at least
six weeks after hospital discharge. They identified an AHI ≥
15 h−1 in 13 of 26 patients (50%) in the first sleep study but
in only 5 of 18 patients (28%) during the second study. In
fact, it has been reported that the AHI obtained by overnight
polysomnography significantly decreases in the CAD chronic
phase (day 14) with respect to the acute phase (days 3–5)
(6.97 ± 5.67 versus 13.26 ± 11.30, resp.) [17]. Moreover, it
seems that alterations in sleep architecture in CAD subjects
tend to decrease over time. In accordance with this line,
Schiza et al. [18] performed a full-night polysomnography
in 22 patients with acute coronary syndrome (ACS) within
3 days of the first episode and 1 and 6 months later. They
found a progressive increase in the total sleep time, sleep
efficiency, slow wave sleep, and rapid eye movement (REM)
sleep. Despite this, an early identification of OSA in subjects
admitted with ACS does not affect the odds of hospital
readmission in the next six months [19]. Possible reasons that
explain why patients in the acute phase of CAD have higher
OSA diagnosis rate have been reported and they are related
to the supine position of patients in the Coronary Care Unit,
the fragmented sleep with reduced rapid eye movement stage
in the first night and finally, the sleep breathing disorders that
produce coronary ischemic diseases by itself (central apneas).
Not all studies have an adequate assessment of condi-
tions that may increase the prevalence of sleep-disordered
breathing, such as sedation or narcotics use, COPD, alco-
holism, level of consciousness, and stroke. Additionally, the
sleep diagnostic tests differ in several studies, and although
attended polysomnography is considered standard practice
in patients with related medical comorbid conditions [13, 17],
many studies have used nonattended sleep studies [14, 15].
Moreover, definitions of respiratory events have not been
homogeneous. For example, Lee et al. [13], consider a 3%
decrease in oxygen saturation to define hypopneas, while
Nakashima et al. [14] considered them when the drop of
oxygen saturation was equal or greater than 4%.
3. Mechanisms of Coronary Artery Disease in
Obstructive Sleep Apnea
Systemic hypertension is a risk factor for the development
of CAD and guidelines for the management of hypertension
consider that OSA contributes directly to the pathogenesis
of hypertension [3, 20]. OSA is characterized by recurrent
episodes of upper airway collapse during sleep, which is
accompanied by cycles of hypoxia-reoxygenation leading
chronic intermittent hypoxia (CIH). In animal models, it
has been shown that intermittent hypoxia could be associ-
ated with the development of hypertension [21]. Moreover,
CIH may affect the plasma renin-angiotensin activity, the
production of endothelin, and the function of peripheral
chemoreceptors, increasing the sympathetic activity [22].
OSA patients have higher plasma and urinary catecholamine
levels than control subjects [23–25] and the disbalance
between sympathetic and parasympathetic systems may
increase systemic vascular resistance and blood pressure [26].
Furthermore, evidence from animal models supports that
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CIH contributes to vascular remodeling [27] andDrager et al.
[28] reported that an increased carotid intima-media thick-
ness is associated to sympathetic activity and atherosclerosis.
OSA patients present systemic inflammation related
to endothelial dysfunction. CIH has been associated with
endothelial dysfunction independently of other risk factors
for atherosclerosis such as obesity, dyslipidemia, diabetes, or
smoking [29].Moreover, patientswithOSAhave an increased
number of apoptotic endothelial cells and fewer circulating
progenitor cells [30, 31]. Finally, endothelial dysfunction has
been also associated with a reduced availability of nitric oxide
in subjects with OSA [29, 32].
The third mechanism involved in the pathogenesis of
CAD in patients with OSA is due to the development of
atherosclerotic plaques through metabolic, oxidative, and
inflammatory pathways. Recurrent episodes of hypoxia are
associated with adipose tissue dysfunction and production
of different adipokines. Increased leptin levels observed
in OSA are related to endothelial dysfunction, production
of cytokines, platelet aggregation, and oxidative stress [33,
34]. Moreover, obstructive apneas downregulate adiponectin
levels, which are closely associated with endothelial dys-
function and atherosclerosis [35]. Furthermore, dyslipi-
demia is present in many OSA subjects and it is char-
acterized by an increased synthesis and secretion of very
LDL-cholesterol and triglycerides and a reduced secretion
of HDL-cholesterol, promoting atherogenesis [36, 37].
Production of some proinflammatory mediators such as
TNF-𝛼, IL-1, IL-8, and adhesion molecules are promoted by
lipid peroxidation and endothelial dysfunction, resulting in
an environment of systemic inflammation. This facilitates
the recruitment and accumulation of macrophages and fat
cells that further activates lipid peroxidation and promotes
endothelial cell damage and atherosclerosis [38, 39]. C-
reactive protein (CRP), another inflammatory biomarker, has
been associated with ACS. Higher CRP levels have been
reported in OSA patients, but it is difficult to tease out the
independent contribution of obesity on the CRP levels [40,
41] (Figure 1).
This inflammatory process associated to CIH, endothelial
dysfunction and atherosclerosis, is induced and regulated by
several transcription factors, such as kappa-B nuclear factor
(NF-kB) and hypoxia inducible factor (HIF)-1𝛼 [42, 43].They
have a key role in the regulation of the innate immunity
and participate actively in inflammatory pathway. Also, in
animal models, they have been implicated in hypertension
and in components of the metabolic syndrome. However, the
potential role of these and other transcription factors in the
pathogenesis of CAD should be further investigated in the
future, and thereby, combining with individual gene analysis
and personalized medicine, may provide new treatment
strategies for cardiovascular protection.
4. Influence of Sleep-Disordered Breathing on
the CAD Prognosis
There has been growing evidence associating OSA with
prognosis of CAD, both in stable and unstable patients.
Peker et al. [44] observed, during a follow-up period of
5 years, the cardiovascular mortality of 62 consecutive
CAD stable patients with and without OSA. They found
6 cardiovascular deaths in OSA patients (37.5%) and 4 in
the non-OSA group (9.3%) (𝑃 = 0.018). Additionally, in
the Cox multiple conditional regression model, respiratory
disturbance index (RDI) was found to be an independent
predictor of cardiovascular mortality (hazard ratio [HR] =
1.13; 95% CI 1.05–1.21, 𝑃 < 0.001). Main limitations of this
study concern aspects that could affect the prevalence ofOSA,
as the type of sleep studies and the timing of OSA screening
(4–21 months after admission).
Moreover, OSA appeared to affect clinical and angio-
graphic outcomes after percutaneous coronary intervention
(PCI) in patients with ACS. In fact, Yumino et al. [45]
performed a sleep study in 89 patients with ACS and, after a
follow-up mean period of 227 days, they observed a higher
incidence of major adverse cardiac events (cardiac death,
reinfarction, and target vessel revascularization) in patients
with OSA (AHI > 10 h−1) (23.5% versus 5.3%, 𝑃 = 0.022).
Furthermore, OSA was an independent predictor for major
adverse cardiac events (HR 11.62, 95% CI 2.17–62.24; 𝑃 =
0.004) and of subsequent angiographic binary restenosis (HR
7.69, 95% CI 1.74–34.05; 𝑃 = 0.007). Evidence linking sleep-
disordered breathing to increased mortality and cardiovas-
cular morbidity has been conflicting and inconclusive in
patients with established CAD. On one hand, Mooe et al.
[46] in a prospective cohort of 408 patients with chronic
CAD followed during a median period of 5.1 years found that
there was a 70% and a 62% relative increase in the primary
end point (composite of death, cerebrovascular events, and
myocardial infarction) in patients with a desaturation index
(DI) ≥ 5 h−1 and an AHI ≥ 10 h−1, respectively. On the other
hand, Hagenah et al. [47] evaluated the prognostic influence
of OSA in 50 patients with stable CAD. After 10 years of
follow-up, they observed thatOSAdid not increase the risk of
mortality and cardiovascular complications. However, both
groups were not fully comparable, having non-OSA patients
with a tendency to more severe coronary lesions.
Myocardial tissue perfusion after primary PCI plays a
pivotal role in recovery of left ventricular function and patient
prognosis in the clinical setting of ACS [48]. Nakashima et al.
[49] used systolic retrograde flow (SRF) and ST-segment
resolution (STR) <50% to measure myocardial tissue per-
fusion immediately after the PCI in 100 patients with ACS.
They performed overnight polysomnography at 14 days of
admission in all patients and they found in the multiple
logistic regression analysis that OSA induced more severe
microvascular injury related to ischemia-reperfusion (SRF:
OR = 4.46, 𝑃 = 0.044; STR: OR = 3.79, 𝑃 = 0.010). However,
Lee et al. [13] did not find similar results. Tomeasure impaired
microvascular perfusion after primary PCI, these authors
used ST-segment resolution of <70%,myocardial blush grade
0 or 1, or a corrected Thrombolysis in Myocardial Infarction
(TIMI) frame count >28. A sleep study was performed and
completed in 105 patients and OSA was not found associated
with impaired microvascular perfusion after primary PCI.
These differences could be related to the different technique
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Figure 1: Development of atherosclerotic plaques in obstructive sleep apnea patients, modified from Na´cher et al. [39].
used to measure myocardial perfusion in both studies. More-
over, differences in the timing of sleep studies (Lee et al.
[13] performed the sleep study 14 to 21 days after hospital
admission, whereas Nakashima et al. [49] did it 2 to 5 days
after hospital admission) could affect the prevalence of OSA
in CAD subjects.
5. CPAP Effect on the Prognosis of
Ischemic Cardiac Disease
Several observational studies have reported that CPAP may
reduce cardiovascular mortality in OSA patients. One study
showed that the incidence of fatal and nonfatal cardiovascular
events during 10 years of follow-up was higher in untreated
severe OSA patients than in patients treated with CPAP or
in healthy subjects [50]. Furthermore, Buchner et al. [51]
reported that treatment of OSA decreases the risk of fatal
and nonfatal cardiovascular events (myocardial infarction,
stroke, and ACS requiring revascularization procedures) in
patients with mild-moderate OSA (HR 0.36, 95% CI 0.21–
0.62, 𝑃 = 0.001) after 72-month follow-up. However, in
this study, the mean duration of follow-up was significantly
different between untreated and treated patients (50.0 ± 49.4
versus 77.0 ± 55.0 months; 𝑃 = 0.001). Moreover, both
Mar´ın et al. and Buchner el al. studies did not have a con-
trolled, randomized design, so their findings could not be
used to make causal inferences.
Few studies have assessed the effects of CPAP on the
morbidity and mortality of CAD patients with OSA, but
some recent reports confirm the possible positive impact
of OSA treatment on the prognosis of CAD. An early
report compared the occurrence of a composite endpoint
(cardiovascular death, ACS, hospitalization for heart failure,
or need for coronary revascularization) between OSA patient
who accepted (CPAP = 11 patients, upper airway surgery =
4 patients) and declined OSA treatment (29 patients). At
the end of follow-up (86.5 ± 39 months), the endpoint was
reached in 6 (24%) and 17 (58%) patients with and without
OSA treatment, respectively (𝑃 < 0.01). Moreover, OSA
treatment reduced in 62% the risk of occurrence of the
composite endpoint (HR 0.24; 95% CI: 0.09–0.62; 𝑃 < 0.01)
[52]. Cassar et al. [53] added further information to the
study of Milleron et al. [52]. They designed a retrospective
cohort study of 371 patients diagnosed with OSA (AHI ≥
15 h−1) who subsequently underwent a PCI and evaluated
cardiac death, generalmortality, major adverse cardiac events
(MACE) (severe angina, myocardial infarction, PCI, coro-
nary artery bypass grafting, or death), and major adverse
cardiac or cerebrovascular events (MACCE). They observed
that patients treated for OSA had a statistically significant
decreased number of cardiac deaths on 5-year follow-up
when comparedwith untreatedOSApatients (3% versus 10%,
𝑃 = 0.027), as well as a trend toward decreased all-cause
mortality (11% versus 17%, 𝑃 = 0.058). However, there was
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Figure 2: Time until first recurrent myocardial infarction (a) or revascularization procedure (b) in the three groups of MI patients. Crude
hazard ratio (HR) of treated versus untreated OSA is presented, reproduced from Garcia-Rio et al. [55].
no difference in the number of MACE or MACCE between
the 2 groups.
Two recent studies performed in Spain have analyzed
the efficacy of CPAP treatment in cardiovascular diseases.
Barbe´ et al. [54], in a multicenter, parallel, randomized
controlled trial, assigned in a 1 : 1 ratio to receive CPAP
treatment or no active intervention in 723 nonsleepy OSA
patients. They compared the incidence of either systemic
hypertension or cardiovascular events (nonfatal myocardial
infarction, nonfatal stroke, transient ischemic attack, hospi-
talization for unstable angina or arrhythmia, heart failure, or
cardiovascular death). At the end of follow-up (4 years), there
were no differences in the hypertension or cardiovascular
event incidence density rate (IDR) betweenCPAPand control
groups.However, in the post hoc analysis, patientswithCPAP
adherence of ≥4 hours per night had a lower incidence of
hypertension or cardiovascular events than control group
(IDR: 0.69, 95% IC 0.50–0.94, 𝑃 = 0.02).
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Recently, we have analyzed the evolution of 192 patients
diagnosed with MI and 96 control subjects after a follow-
up period of 6.5 years. OSA was an independent predictor
of AMI (OR 4.9, IC 95% 2.9–8.3, 𝑃 = 0.017), with directly
proportional relationship. Furthermore, we have observed
that treated OSA patients had a lower risk of recurrent AMI
(HR 0.16, IC 95% 0.03–0.76,𝑃 = 0.021) and revascularization
(HR 0.15, IC 95% 0.03–0.79, 𝑃 = 0.025) than untreated
OSA patients, but a similar risk to non-OSA patients [55]
(Figure 2).
6. Conclusions
OSA is a common condition that is associated with several
cardiovascular complications such as CAD.The CAD patho-
genesis in OSA is complex and probably related to increased
sympathetic activity, endothelial dysfunction, and atheroscle-
rosis. In addition, abnormal lipid metabolism related to
OSA could also participate in the pathogenesis of CAD.
Several studies have reported an association between OSA
and CAD in stable and unstable patients. Furthermore,
the prognosis of subjects with coronary disease could be
affected by the presence and the severity of OSA. Finally,
there is evidence that OSA treatment with CPAP reduces the
mortality and morbidity of CAD patients, but there is still
a need for long-term data to confirm the benefit of CPAP
treatment.
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